{"id":"pegylated-interferon-ribavirin-boceprevir","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Anemia"},{"rate":"50-70","effect":"Fatigue"},{"rate":"30-40","effect":"Headache"},{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Dysgeusia (taste disturbance)"},{"rate":"10-20","effect":"Neutropenia"},{"rate":"5-15","effect":"Thrombocytopenia"},{"rate":"10-20","effect":"Depression/mood changes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pegylated interferon stimulates the innate immune system to attack HCV-infected cells. Ribavirin is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase and reduces viral mutation rates. Boceprevir is a direct-acting antiviral that specifically inhibits the HCV NS3/4A serine protease, which is essential for viral polyprotein processing and replication.","oneSentence":"This triple-drug combination inhibits hepatitis C virus replication by boosting interferon-mediated antiviral immunity, blocking viral RNA synthesis, and directly inhibiting the NS3/4A protease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:59.998Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotype 1)"}]},"trialDetails":[{"nctId":"NCT01482767","phase":"PHASE3","title":"Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-04","conditions":"HIV Infections, Hepatitis C","enrollment":262},{"nctId":"NCT01425203","phase":"PHASE3","title":"The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-23","conditions":"Chronic Hepatitis C Genotype 1","enrollment":238},{"nctId":"NCT01390844","phase":"PHASE3","title":"Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-21","conditions":"Hepatitis C, Chronic","enrollment":282},{"nctId":"NCT02758509","phase":"","title":"Impact of Antiviral Therapy on Gastroesophageal Varices.","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2010-01-01","conditions":"Chronic Hepatitis C, Cirrhosis","enrollment":237},{"nctId":"NCT00959699","phase":"PHASE2","title":"A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"HIV Infections, Hepatitis C, HCV Infection","enrollment":99},{"nctId":"NCT00708500","phase":"PHASE3","title":"Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Hepatitis C, Chronic","enrollment":404},{"nctId":"NCT01447446","phase":"","title":"An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Hepatitis C, Chronic","enrollment":4442},{"nctId":"NCT01925183","phase":"PHASE4","title":"Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C","status":"COMPLETED","sponsor":"Markus Peck-Radosavljevic","startDate":"2013-08","conditions":"Hepatitis C, Chronic, HIV","enrollment":6},{"nctId":"NCT01463956","phase":"PHASE2","title":"Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2012-01-06","conditions":"HCV Infection, Liver Cirrhosis, Experimental","enrollment":58},{"nctId":"NCT01514890","phase":"","title":"French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2011-02","conditions":"Chronic Hepatitis C","enrollment":675},{"nctId":"NCT01446250","phase":"PHASE3","title":"Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1","status":"TERMINATED","sponsor":"Debiopharm International SA","startDate":"2011-12","conditions":"Hepatitis C","enrollment":8},{"nctId":"NCT02118597","phase":"","title":"An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2014-05","conditions":"Hepatitis C, Chronic","enrollment":19},{"nctId":"NCT02057003","phase":"","title":"Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients","status":"UNKNOWN","sponsor":"Valme University Hospital","startDate":"2012-01","conditions":"Hepatitis C, Chronic, Human Immunodeficiency Virus","enrollment":1000},{"nctId":"NCT02877199","phase":"","title":"Anti-E1E2 Antibodies (D32.10 Epitope-binding Antibodies) and HCV Triple Therapy","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2014-06","conditions":"Hepatitis C","enrollment":19},{"nctId":"NCT01482403","phase":"PHASE2","title":"A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11","conditions":"Hepatitis C, Chronic","enrollment":58},{"nctId":"NCT02204475","phase":"PHASE3","title":"Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-11","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT02112630","phase":"NA","title":"Boceprevir in End Stage Renal Disease (ESRD)","status":"WITHDRAWN","sponsor":"Columbia University","startDate":"2013-05","conditions":"Hepatitis C Infection, End Stage Renal Disease","enrollment":""},{"nctId":"NCT01465516","phase":"","title":"Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir","status":"TERMINATED","sponsor":"Arrowhead Regional Medical Center","startDate":"2011-11","conditions":"Hepatitis C Infection","enrollment":105},{"nctId":"NCT01405027","phase":"PHASE4","title":"Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy","status":"COMPLETED","sponsor":"Chronic Liver Disease Foundation","startDate":"2011-12","conditions":"Chronic Hepatitis C, Genotype 1","enrollment":197},{"nctId":"NCT02160080","phase":"PHASE3","title":"Boceprevir Treatment in Liver Pre-transplant HCV Patients","status":"UNKNOWN","sponsor":"Hu Tsung-Hui","startDate":"2014-01","conditions":"Late Complication From Liver Transplant","enrollment":20},{"nctId":"NCT01457937","phase":"PHASE3","title":"Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)","status":"UNKNOWN","sponsor":"University of Modena and Reggio Emilia","startDate":"2011-11","conditions":"Chronic Hepatitis C, Menopause","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PEG IFN alfa 2b : Peg Intron","Ribavirin: Rebetol","Boceprevir: Victrelis"],"phase":"phase_3","status":"active","brandName":"Pegylated Interferon, Ribavirin, Boceprevir","genericName":"Pegylated Interferon, Ribavirin, Boceprevir","companyName":"University of Modena and Reggio Emilia","companyId":"university-of-modena-and-reggio-emilia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple-drug combination inhibits hepatitis C virus replication by boosting interferon-mediated antiviral immunity, blocking viral RNA synthesis, and directly inhibiting the NS3/4A protease. Used for Chronic hepatitis C virus infection (genotype 1).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}